Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 9, 2007 Brian Lawler	Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing.
The Motley Fool January 10, 2007 Brian Lawler	Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result.
The Motley Fool September 14, 2010 Brian Orelli	This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool January 22, 2008 Brian Lawler	Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool April 30, 2007 Brian Lawler	The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note.
The Motley Fool September 27, 2010 Brian Orelli	Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
The Motley Fool January 6, 2011 Brian Orelli	$145 Million Down; Billions to Go Seattle Genetics signs up another partner.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool July 13, 2011 Brian Orelli	2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool March 31, 2008 Brian Lawler	A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
The Motley Fool November 6, 2007 Brian Lawler	It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results.
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool August 29, 2006 Brian Lawler	More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note.
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.
Bio-IT World May 19, 2004 Barbara Depompa	Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool October 9, 2006 Brian Lawler	Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note.